MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

StatusCompleted
PhasePhase 2
SponsorPfizer
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 53 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Trial sites expanded: 40 → 78 locations
    • Study completion date changed from estimate of Dec 31, 2026 to Aug 25, 2026
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 16 of 21 entries
    • Publications: details revised at 10 of 10 entries
  2. Study sites: 87 to 40v52
  3. Study sites: 89 to 87v51
  4. Study sites: 85 to 89v50
  5. Study sites: 73 to 85
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v49
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 79 to 73v48
  2. Re-verified, no change to tracked fieldsv47
  3. Study sites: 78 to 79v46
  4. Enrollment target: 188 to 187v45
  5. Study sites: 77 to 78v44
  6. Enrollment target: 187 to 188v43
  7. Study completion date: Apr 6, 2024 to Dec 31, 2025v42
  8. Results first posted: Oct 25, 2023v41 Show 4 more changesShow less
    • Enrollment target: 188 to 187
    • Study sites: 76 to 77
    • Study completion date: Jan 9, 2024 to Apr 6, 2024
    • Secondary endpoints: details revised at 20 of 21 entries
  9. Primary endpoint revised
    • Enrollment target: 187 to 188
    • Secondary endpoints: 12 to 21
    v40
  10. Re-verified, no change to tracked fieldsv39
  11. Enrollment target: estimated 180 to confirmed 187v38
  12. Enrollment target: 188 to 180
    • Secondary endpoints: 11 to 12
    v37
  13. Re-verified, no change to tracked fieldsv36
  14. Study sites: 77 to 76v35
  15. Enrollment target: estimated 180 to confirmed 188
    • Study sites: 76 to 77
    • Primary completion date: Jul 1, 2022 to Jun 17, 2022
    v34
  16. Study sites: 77 to 76
    • Primary completion date: Sep 16, 2022 to Jul 1, 2022
    v33
  17. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 95 to 77
    v32
  18. Study sites: 96 to 95v31
  19. Enrollment target: 150 to 180
    • Secondary endpoints revised (11)
    • Site details revised at 1 of 96 sites
    v30
  20. Study sites: 97 to 96v29
  21. Study sites: 95 to 97v28
  22. Study sites: 88 to 95v27
  23. Study sites: 89 to 88v26
  24. Study sites: 88 to 89v25
  25. Study sites: 85 to 88v24
  26. Study sites: 83 to 85v23
  27. Study sites: 77 to 83v22
  28. Study sites: 72 to 77v21
  29. Study sites: 70 to 72v20
  30. Study sites: 64 to 70v19
  31. Site details revised at 2 of 64 sitesv18
  32. Study sites: 43 to 64
    • Primary completion date: Sep 28, 2022 to Sep 16, 2022
    • Study completion date: Jan 21, 2024 to Jan 9, 2024
    v17
  33. Study sites: 39 to 43v16
  34. Study sites: 34 to 39v15
  35. Study sites: 30 to 34
    • Primary completion date: Sep 17, 2022 to Sep 28, 2022
    • Study completion date: Jan 10, 2024 to Jan 21, 2024
    v14
  36. Study sites: 27 to 30v13
  37. Study sites: 25 to 27
    • Primary completion date: Sep 1, 2022 to Sep 17, 2022
    • Study completion date: Dec 25, 2023 to Jan 10, 2024
    v12
  38. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised at 25 of 25 sites
    v11
  39. Enrollment target: 4 to 150v10
  40. Primary completion date: Jun 25, 2022 to Sep 1, 2022v9 Show 4 more changesShow less
    • Study completion date: Oct 18, 2023 to Dec 25, 2023
    • Interventions: PF-06863135 (Drug) to Elranatamab (PF-06863135) (Drug)
    • Eligibility criteria expanded, about 31 words
    • Secondary endpoints revised (11)
  41. Enrollment target: estimated 150 to confirmed 4
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 23 to 25
    v8
  42. Study sites: 17 to 23v7
  43. Study sites: 6 to 17v6
  44. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 6 of 6 sites
    • Study title expanded, about 2 words
    v5
  45. Study sites: 1 to 6v4 Show 4 more changesShow less
    • Study completion date: Oct 17, 2026 to Oct 18, 2023
    • Start date: Jan 14, 2021 to Feb 2, 2021
    • Secondary endpoints: details revised at 1 of 11 entries
    • Eligibility criteria shortened, about 2 words
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
438 trials monitored
See 32 trials at risk
Multiple Myeloma
1,264 trials monitored
See 78 trials at risk
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Trial Details
NCT Number NCT04649359
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma, Neoplasms, Plasma Cell
Enrollment 187 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov